Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP914080.RARtnNdizuCtut6WUCLE82DE1F_80iHnwfKrtjPbBW-tI130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914080.RARtnNdizuCtut6WUCLE82DE1F_80iHnwfKrtjPbBW-tI130_provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1005413.RAXAb4P0eB_xXp2vCaAtFcCdAgQVHtHYUMa6G4Jujwjsw130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005413.RAXAb4P0eB_xXp2vCaAtFcCdAgQVHtHYUMa6G4Jujwjsw130_provenance.
• NP1005424.RAaI9T88VuJiES4lscXitTGEAqMW3RzbCx0G8AjBlKp1U130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005424.RAaI9T88VuJiES4lscXitTGEAqMW3RzbCx0G8AjBlKp1U130_provenance.
• NP1005426.RAQSNUq1EV3qTsa6f6u3MTQ7xESYUI3qyrq8GCb-siC6g130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005426.RAQSNUq1EV3qTsa6f6u3MTQ7xESYUI3qyrq8GCb-siC6g130_provenance.
• NP978568.RAAbef-ePupApkOnaS_atvTUkkORxBRPk4Yv3rZe6xxwg130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978568.RAAbef-ePupApkOnaS_atvTUkkORxBRPk4Yv3rZe6xxwg130_provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1005421.RADU1B9O6ux5mg6C1ER6erp49p9w103cOazdidkhN8j7M130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005421.RADU1B9O6ux5mg6C1ER6erp49p9w103cOazdidkhN8j7M130_provenance.
• NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_provenance.
• NP873226.RAtD-kshYjWRsCLU-X35x_LHuyWRqOwnTn91AHhpjXYKM130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873226.RAtD-kshYjWRsCLU-X35x_LHuyWRqOwnTn91AHhpjXYKM130_provenance.
• NP873379.RAqErHiFgXcBN9LElpvkjYxarZu531IeAMp8Y5x7pWxo8130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873379.RAqErHiFgXcBN9LElpvkjYxarZu531IeAMp8Y5x7pWxo8130_provenance.
• NP1005412.RAs6dXNXWtD7oAMmg2L7xwA26gSJLCwYAyzBfFeSiBl40130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005412.RAs6dXNXWtD7oAMmg2L7xwA26gSJLCwYAyzBfFeSiBl40130_provenance.
• NP1005419.RAt8GiHVlSg-WjILvSK8hyb2ghheaIbMGF_L9Gaqcpkbw130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005419.RAt8GiHVlSg-WjILvSK8hyb2ghheaIbMGF_L9Gaqcpkbw130_provenance.
• NP1005422.RAvNI0w6gw0IX5agOAO2V7yeL4wcxFC1C7QGeHjblnPDw130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005422.RAvNI0w6gw0IX5agOAO2V7yeL4wcxFC1C7QGeHjblnPDw130_provenance.
• NP605993.RAzT79Fb5ds9guoStfOxnkQnWTwrMI-CZWf8kPR03fapQ130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605993.RAzT79Fb5ds9guoStfOxnkQnWTwrMI-CZWf8kPR03fapQ130_provenance.
• NP606228.RA9DVA5omw7h4hBsVnNL8jq6ktgcwEjBAxRIczJ8h6g9A130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606228.RA9DVA5omw7h4hBsVnNL8jq6ktgcwEjBAxRIczJ8h6g9A130_provenance.
• NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_provenance.
• NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
• NP781464.RAJir6Aj3apL0kKBMxfqN9uVO_JDei6Pq3oTQi_ERZBy4130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781464.RAJir6Aj3apL0kKBMxfqN9uVO_JDei6Pq3oTQi_ERZBy4130_provenance.
• NP781642.RAHe0N0u-xFK8PZ6Jr7pqRX94lIpvxzp4Egcc0rdfueoQ130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781642.RAHe0N0u-xFK8PZ6Jr7pqRX94lIpvxzp4Egcc0rdfueoQ130_provenance.
• NP1005414.RALQmBkMXAbmnVXo2DvJb5EzJKf3YhpdsAltA-VX5uj_I130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005414.RALQmBkMXAbmnVXo2DvJb5EzJKf3YhpdsAltA-VX5uj_I130_provenance.
• NP1005420.RAOtRabam5KrEWeb6Y8maNTzWmHdHCzlbwMp-Po8dleCg130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005420.RAOtRabam5KrEWeb6Y8maNTzWmHdHCzlbwMp-Po8dleCg130_provenance.
• NP1005423.RANkuYCW9g7zs6Ddu7X2nGNlVbc_OgBJM8cxUaQ-oJdYk130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005423.RANkuYCW9g7zs6Ddu7X2nGNlVbc_OgBJM8cxUaQ-oJdYk130_provenance.
• NP914262.RAyCLBUCyR655eotg4cjo4t3z9PPL0uA-F2heZhnH3B7U130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914262.RAyCLBUCyR655eotg4cjo4t3z9PPL0uA-F2heZhnH3B7U130_provenance.
• NP1005415.RA2jLV4_jLOcQNGObjqQnKtal_-DhnWDbXPHTVpoCCz1U130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005415.RA2jLV4_jLOcQNGObjqQnKtal_-DhnWDbXPHTVpoCCz1U130_provenance.
• NP1005416.RA4q0SOvVfafofA8XSkv-LROgKvPfLEaC8xG7Khb-b_zw130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005416.RA4q0SOvVfafofA8XSkv-LROgKvPfLEaC8xG7Khb-b_zw130_provenance.
• NP1005417.RA6ywdDol1DIrAy0RqKh3x5etNQaOD4Qar4CJvth_4b4M130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005417.RA6ywdDol1DIrAy0RqKh3x5etNQaOD4Qar4CJvth_4b4M130_provenance.
• NP1005418.RAx3fiivCCtlAqebRL6g-jzmW-x9otqp908TlCKcOv2ek130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005418.RAx3fiivCCtlAqebRL6g-jzmW-x9otqp908TlCKcOv2ek130_provenance.
• NP1005425.RA08fn7le0zV2j4lNILQke8-KyU9TXZnGiaitdn2eu0MQ130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005425.RA08fn7le0zV2j4lNILQke8-KyU9TXZnGiaitdn2eu0MQ130_provenance.